LIDOCAINE HCL 0.8% AND 5% DEXTROSE INJ 50 MG — DIN 00828610
DEXTROSE : 50 MG LIDOCAINE HYDROCHLORIDE : 8 MG · BAXTER CORPORATION · SOLUTION · wholesale supply in Canada
Health Canada status: CANCELLED POST MARKET
What is LIDOCAINE HCL 0.8% AND 5% DEXTROSE INJ?
LIDOCAINE HCL 0.8% AND 5% DEXTROSE INJ 50 MG contains DEXTROSE : 50 MG LIDOCAINE HYDROCHLORIDE : 8 MG. It is listed in the Health Canada Drug Product Database under DIN 00828610, held by BAXTER CORPORATION, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as cancelled post market, status dated 02-Feb-2016. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
How much does Lidocaine cost around the world?
Lidocaine is listed on 14 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Austria publishes a KVP (Kassenverkaufspreis); Bahrain publishes a retail (max). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| United States | acquisition | 25 | 121 | USD███.██ |
| United Kingdom | hospital | 22 | 22 | GBP███.██ |
| United Arab Emirates | public | 11 | 16 | AED███.██ |
| Bahrain | retail (max) | 11 | 14 | BHD███.██ |
| South Africa | single exit price | 7 | 12 | ZAR███.██ |
| Greece | producer price (ex-factory) | 9 | 9 | EUR███.██ |
| Saudi Arabia | public | 6 | 9 | SAR███.██ |
| Morocco | PPV (public price) | 8 | 8 | MAD███.██ |
| Austria | KVP (Kassenverkaufspreis) | 4 | 4 | EUR███.██ |
| Australia | ex-manufacturer | 3 | 3 | AUD███.██ |
| Luxembourg | reimbursement | 3 | 3 | EUR███.██ |
| Iceland | max wholesale | 2 | 2 | ISK███.██ |
| Czechia | max producer price (ex-factory) | 1 | 1 | CZK███.██ |
| Lebanon | public price (USD, Decision 119/1) | 1 | 1 | USD███.██ |
225 pack listings across 113 brand entries and 13 price bases, refreshed 08 Sep 2026. Ranges span every Lidocaine pack in that market, so a high figure is usually a larger pack rather than the same product.
This table is a regulatory record of where the molecule is listed. The DIN on this page is no longer authorized for sale in Canada, so Nexara does not quote it — see the alternatives above.
Is there a generic Lidocaine in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
8 holders have a Canadian DIN containing Lidocaine, across 13 DINs, of which 4 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| BAXTER CORPORATION | 3 | 1 | 0.4% LIDOCAINE HYDROCHLORIDE AND 5% DEXTROSE INJECTION, LIDOCAINE HCL 0.2% AND DEXTROSE 5% INJ, LIDOCAINE HCL 0.8% AND 5% DEXTROSE INJ | Sourceable in Canada |
| ASPEN PHARMACARE CANADA INC. | 1 | 1 | XYLOCARD | Sourceable in Canada |
| LABORATOIRE AGUETTANT | 1 | 1 | LIDOCAINE HYDROCHLORIDE INJECTION | Sourceable in Canada |
| PFIZER CANADA ULC | 1 | 1 | LIDOCAINE HYDROCHLORIDE INJECTION USP | Sourceable in Canada |
| B. BRAUN MEDICAL INC | 3 | 0 | LIDOCAINE HCL AND DEXTROSE 5% INJ USP, LIDOCAINE HYDROCHLORIDE AND 5% DEXTROSE INJECTION USP | No marketed DIN |
| HOSPIRA HEALTHCARE ULC | 2 | 0 | 0.4% LIDOCAINE HYDROCHLORIDE AND 5% DEXTROSE INJECTION USP, LIDOCAINE 0.2% IN 5% DEXTROSE INJ | No marketed DIN |
| ASTRA PHARMA INC. | 1 | 0 | XYLOCARD ONE GM ADDITIVE UNIT 20% INJ | No marketed DIN |
| INTERNATIONAL MEDICATION SYSTEMS LTD. | 1 | 0 | LIDOCAINE HCL INJ 20MG/ML | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 50 MG |
|---|---|
| Dosage form | SOLUTION |
| Route | INTRAVENOUS |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Lidocaine |
|---|---|
| ATC code | C01BB01 |
| AHFS class | 24:04.04.08 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 00828610 |
|---|---|
| DIN (unpadded, as printed on some documents) | 828610 |
| Brand name | LIDOCAINE HCL 0.8% AND 5% DEXTROSE INJ |
| Generic / active ingredient | DEXTROSE : 50 MG LIDOCAINE HYDROCHLORIDE : 8 MG |
| Market authorization holder | BAXTER CORPORATION |
| Health Canada schedule | Ethical |
| ATC code | C01BB01 |
| ATC anatomical main group | C — Cardiovascular system |
| ATC therapeutic subgroup | C01BB |
| Current status | CANCELLED POST MARKET |
| Status date | 02-Feb-2016 |
| Original market date | 1990-12-31 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
Is Lidocaine in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Anticipated — reported by HIKMA CANADA LIMITED, last seen 09 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
Check availability for LIDOCAINE HCL 0.8% AND 5% DEXTROSE INJ
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
4 of 13 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| 0.4% LIDOCAINE HYDROCHLORIDE AND 5% DEXTROSE INJECTION | 4 MG | SOLUTION | BAXTER CORPORATION | MARKETED | 00828602 |
| LIDOCAINE HYDROCHLORIDE INJECTION | 100 MG / 5 ML | SOLUTION | LABORATOIRE AGUETTANT | MARKETED | 02522268 |
| LIDOCAINE HYDROCHLORIDE INJECTION USP | 20 MG | SOLUTION | PFIZER CANADA ULC | MARKETED | 00436208 |
| XYLOCARD | 100 MG / 5 ML | SOLUTION | ASPEN PHARMACARE CANADA INC. | MARKETED | 00001937 |
| 0.4% LIDOCAINE HYDROCHLORIDE AND 5% DEXTROSE INJECTION USP | 4 MG | SOLUTION | HOSPIRA HEALTHCARE ULC | CANCELLED POST MARKET | 00478288 |
| LIDOCAINE 0.2% IN 5% DEXTROSE INJ | 50 MG | SOLUTION | HOSPIRA HEALTHCARE ULC | CANCELLED POST MARKET | 00478296 |
| LIDOCAINE HCL 0.2% AND DEXTROSE 5% INJ | 50 MG | SOLUTION | BAXTER CORPORATION | CANCELLED POST MARKET | 00828599 |
| LIDOCAINE HCL AND DEXTROSE 5% INJ USP | 5 G / 100 ML | SOLUTION | B. BRAUN MEDICAL INC | CANCELLED POST MARKET | 01935968 |
| LIDOCAINE HCL AND DEXTROSE 5% INJ USP | 400 MG / 100 ML | SOLUTION | B. BRAUN MEDICAL INC | CANCELLED POST MARKET | 01935976 |
| LIDOCAINE HCL INJ 20MG/ML | 20 MG | LIQUID | INTERNATIONAL MEDICATION SYSTEMS LTD. | CANCELLED POST MARKET | 00565032 |
2 · Same class — other molecules in ATC C01BB
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Lidocaine | 0.4% LIDOCAINE HYDROCHLORIDE AND 5% DEXTROSE INJECTION · 0.4% LIDOCAINE HYDROCHLORIDE AND 5% DEXTROSE INJECTION USP · LIDOCAINE 0.2% IN 5% DEXTROSE INJ · LIDOCAINE HCL 0.2% AND DEXTROSE 5% INJ · +8 more | 13 | 4 | Yes |
| Mexiletine | ALTI-MEXILETINE · MEXITIL CAP 100MG · MEXITIL CAP 200MG · MINT-MEXILETINE · +1 more | 8 | 4 | Yes |
| Tocainide | TONOCARD TAB 400 MG | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC C01B
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| C01BC | Flecainide · Propafenone | 35 | 16 |
| C01BD | Amiodarone · Bretylium Tosilate · Dronedarone · Ibutilide | 43 | 14 |
| C01BA | Disopyramide · Procainamide · Quinidine | 44 | 1 |
| C01BG | Vernakalant | 1 | 1 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is LIDOCAINE HCL 0.8% AND 5% DEXTROSE INJ called?
The same molecule, Lidocaine, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Lignox | Latin | Saudi Arabia |
| VERSATIS | Latin | Bahrain, Czechia |
| Depo-medrol with Lidocaine | Latin | South Africa |
| Lidocaine Eva | Latin | Saudi Arabia |
| PLIAGLIS | Latin | Bahrain |
| Pliaglis® | Latin | United Arab Emirates |
| PRILA | Latin | Bahrain |
| Xylocaine | Latin | Bahrain, South Africa |
| xylocream® | Latin | United Arab Emirates |
| AVOCAINE | Latin | Bahrain |
| BelOcain vet. | Latin | Iceland |
| EMLA | Latin | Bahrain |
| Ennla | Latin | Saudi Arabia |
| Haemoproct | Latin | United Arab Emirates |
| Haemoproct Cream | Latin | United Arab Emirates |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.